Log in
Enquire now
‌

US Patent 10472613 Method for modulating car-induced immune cells activity

Patent 10472613 was granted and assigned to Cellectis on November, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Cellectis
Cellectis
0
Current Assignee
Cellectis
Cellectis
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
104726130
Patent Inventor Names
Alexandre Juillerat0
Laurent Poirot0
Philippe Duchateau0
Date of Patent
November 12, 2019
0
Patent Application Number
155177080
Date Filed
October 7, 2015
0
Patent Citations Received
0
‌
US Patent 11655452 Chimeric antigen receptors (CARs), compositions and methods of use thereof
0
Patent Primary Examiner
‌
Sean E Aeder
0
Patent abstract

The present invention relates to a method to modulate the level of activation of an engineered immune cell (such as a Chimeric Antigen Receptor T-cell) for immunotherapy. The present invention also relates to cells obtained by the present method, preferably comprising said modulable/tunable chimeric antigen receptors for use in therapeutic or prophylactic treatment.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10472613 Method for modulating car-induced immune cells activity

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.